Skip to main content
. Author manuscript; available in PMC: 2023 Dec 21.
Published in final edited form as: Ann Oncol. 2023 Jun 9;34(9):783–795. doi: 10.1016/j.annonc.2023.05.012

Figure 2. Association of HER2DX pCR groups with response to dual HER2 blockade and with response to multi-agent chemotherapy in the combined neoadjuvant cohort.

Figure 2.

(A) Bar plots showing the pCR rates across the HER2DX pCR groups based on single versus dual HER2 blockade. (B) Forest plots evaluating the association of HER2DX pCR groups with pCR according to dual HER2 blockade administration in cohorts that compared dual blockade vs. single anti-HER2 (DAPHNe, BiOnHER and PAMELA cohorts were not included). (C) Bar plots showing the pCR rates across the HER2DX pCR groups based on single taxane versus multi-agent chemotherapy in the cohort of 367 patients treated with dual HER2 blockade. OR: odds ratio; 95% CI: 95% confidence interval; pCR: pathological complete response.